ψ-Bufarenogin, a lead compound of anti-cancer drug

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cell Cycle

• Publication date

  2015-08-27

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/15384101.2015.1071139PMID 26312642PMCID PMC4614062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The global burden of liver disease: The major impact of China

  2014cited by this paper
• Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

  2013cited by this paper
• Lineage Tracing Reveals Lgr5+ Stem Cell Activity in Mouse Intestinal Adenomas

  2012cited by this paper
• Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

  2011cited by this paper
• Purification of active bufadienolides from toad skin by preparative reversed-phase liquid chromatography coupled with hydrophilic interaction chromatography.

  2010cited by this paper
• Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells.

  2010cited by this paper
• Lessons from natural molecules

  2004cited by this paper

• Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer

  2024cites this paper
• Novel Strategies for Solubility and Bioavailability Enhancement of Bufadienolides

  2021cites this paper
• Lead Compounds in the Context of Extracellular Vesicle Research

  2020cites this paper
• Application of highly efficient and lowly toxic bufadienolides screened from toad skin in lymphatic chemotherapy for colorectal cancer through a lymphatic metastatic model

  2019cites this paper